GlassScriptPhysician profile
Brian Saw Ming Tan
NPI 1790125060
$5,165.46
in general payments reported to CMS, 2019-2025
22 companies · $873 in 2025
The $873 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2020: $220 · 2021: $390 · 2022: $700 · 2023: $1,027 · 2024: $1,228 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,128.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,107.03 | 2019-2025 | Cequa |
| Alcon Vision LLC | $793.05 | 2019-2025 | Wavelight Refractive Suite, Clareon, Rocklatan |
| Bausch & Lomb Americas INC. | $724.97 | 2022-2025 | Miebo, Xiidra, Infuse |
| Abbvie INC. | $492.04 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Harrow Eye, LLC | $405.31 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $261.12 | 2019-2023 | |
| Oyster Point Pharma, INC. | $250.00 | 2022-2023 | Tyrvaya |
| Allergan, INC. | $234.55 | 2019-2022 | |
| Dompe US, INC. | $151.12 | 2024-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $107.49 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $107.47 | 2019-2025 | |
| Shire North American Group INC | $104.08 | 2019 | |
| Optos, INC. | $91.71 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $84.60 | 2025 | |
| Johnson & Johnson Surgical Vision, INC. | $74.01 | 2019-2024 | Tecnis Iol |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $63.97 | 2019-2021 | |
| Genentech USA, INC. | $27.67 | 2025 | Vabysmo |
| Aerie Pharmaceuticals, INC. | $23.34 | 2021 | |
| Kala Pharmaceuticals, INC. | $19.92 | 2021 | |
| Thea Pharma INC. | $14.41 | 2025 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.22 | 2021 | |
| Coopervision INC. | $13.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.